Cargando…
Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies
BACKGROUND: Accurate assessments of patient response to therapy are a critical component of personalized medicine. In glioblastoma (GBM), the most aggressive form of brain cancer, tumor growth dynamics are heterogenous across patients, complicating assessment of treatment response. This study aimed...
Autores principales: | Singleton, Kyle W, Porter, Alyx B, Hu, Leland S, Johnston, Sandra K, Bond, Kamila M, Rickertsen, Cassandra R, De Leon, Gustavo, Whitmire, Scott A, Clark-Swanson, Kamala R, Mrugala, Maciej M, Swanson, Kristin R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447137/ https://www.ncbi.nlm.nih.gov/pubmed/32864609 http://dx.doi.org/10.1093/noajnl/vdaa085 |
Ejemplares similares
-
Assessment of Prognostic Value of Cystic Features in Glioblastoma Relative to Sex and Treatment With Standard-of-Care
por: Curtin, Lee, et al.
Publicado: (2020) -
Shape matters: morphological metrics of glioblastoma imaging abnormalities as biomarkers of prognosis
por: Curtin, Lee, et al.
Publicado: (2021) -
Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma
por: Massey, Susan Christine, et al.
Publicado: (2020) -
Sex-specific impact of patterns of imageable tumor growth on survival of primary glioblastoma patients
por: Whitmire, Paula, et al.
Publicado: (2020) -
VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance
por: Michaelsen, Signe R, et al.
Publicado: (2018)